Clinical trials: Adamantinous Craniopharyngioma
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2.
- Trial name
- NCT05286788
- Testing
- Binimetinib Oral Tablet [Mektovi]
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 38 people
- Sponsor
- Nationwide Children's Hospital
Adamantinomatous Craniopharyngioma
Tocilizumab in Children With ACP
This study will be conducted in two phases. The first phase (phase 0) will be looking at patients with new or recurrent/ progressed craniopharyngioma tumors.
- Trial name
- NCT03970226
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis.
- Trial name
- NCT05233397
- Testing
- Tocilizumab
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Nationwide Children's Hospital